Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo

Despite more than 300,000 rVSVΔG-ZEBOV-glycoprotein (GP) vaccine doses having been administered during Ebola virus disease (EVD) outbreaks in the Democratic Republic of the Congo (DRC) between 2018 and 2020, seroepidemiologic studies of vaccinated Congolese populations are lacking. This study examin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoff, Nicole A., Bratcher, Anna, Kelly, J. Daniel, Musene, Kamy, Kompany, Jean Paul, Kabamba, Michel, Mbala-Kingebeni, Placide, Dighero-Kemp, Bonnie, Kocher, Gregory, Elliott, Elizabeth, Reilly, Cavan, Halbrook, Megan, Ilunga Kebela, Benoit, Gadoth, Adva, Ngoie Mwamba, Guillaume, Tambu, Merly, McIlwain, David R., Mukadi, Patrick, Hensley, Lisa E., Ahuka-Mundeke, Steve, Rutherford, George W., Muyembe-Tamfum, Jean Jacques, Rimoin, Anne W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833182/
https://www.ncbi.nlm.nih.gov/pubmed/35110410
http://dx.doi.org/10.1073/pnas.2118895119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833182/
https://www.ncbi.nlm.nih.gov/pubmed/35110410
http://dx.doi.org/10.1073/pnas.2118895119

Ejemplares similares